In the subgroup with MetS alone, metformin improved insulin sensitivity and modestly reduced weight—effects that align with previous studies emphasizing its utility in managing hyperinsulinemia and obesity in normoglycemic individuals [20, 53]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.